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Lack of Reduction of Left Ventricular Mass in Treated Hypertension:
The Strong Heart Study
Giovanni de Simone, MD; Richard B. Devereux, MD; Raffaele Izzo, MD, PhD; Daniela Girfoglio, MD; Elisa T. Lee, PhD;
Barbara V. Howard, PhD; Mary J. Roman, MD
Background-—Hypertensive left ventricular mass (LVM) is expected to decrease during antihypertensive therapy, based on results
of clinical trials.
Methods and Results-—We assessed 4-year change of echocardiographic LVM in 851 hypertensive free-living participants of the
Strong Heart Study (57% women, 81% treated). Variations of 5% or more of the initial systolic blood pressure (SBP) and LVM
were categorized for analysis. At baseline, 23% of men and 36% of women exhibited LV hypertrophy (LVH, P<0.0001). At the
follow-up, 3% of men and 10% of women had regression of LVH (P<0.0001 between genders); 14% of men and 15% of women,
free of baseline LVH, developed LVH. There was an increase in LVM over time, more in men than in women (P<0.001).
Participants whose LVM did not decrease had similar baseline SBP and diastolic BP, but higher body mass index (BMI), waist/
hip ratio, heart rate (all P<0.008), and urinary albumin/creatinine excretion (P<0.001) than those whose LVM decreased. After
adjusting for ﬁeld center, initial LVM index, target BP, and kinship degree, lack of decrease in LVM was predicted by higher
baseline BMI and urinary albumin/creatinine excretion, independently of classes of antihypertensive medications, and signiﬁcant
effects of older age, male gender, and percentage increase in BP over time. Similar ﬁndings were obtained in the subpopulation
(n=526) with normal BP at follow-up.
Conclusions-—In a free-living population, higher BMI is associated with less reduction of hypertensive LVH; lack of reduction of
LVM is independent of BP control and of types of antihypertensive treatment, but is associated with renal damage. ( J Am Heart
Assoc. 2013;2:e000144 doi: 10.1161/JAHA.113.000144)
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C linical trials almost invariably indicate that reduction ofhypertensive left ventricular mass (LVM) is an achiev-
able goal during antihypertensive management1–5 and that
this reduction results in a decreased incidence of cardio-
vascular (CV) events,6,7 independently of reduction in blood
pressure (BP) and other factors that decrease CV risk.
However, the translation of these ﬁndings into clinical
practice is made difﬁcult by a number of critical issues,
including selection of patients, deﬁnition of hypertensive LV
hypertrophy (LVH), and relation to BP control.8 There are
also issues related to the standardized trial environment,
which is not automatically reproducible in real life clinical
practice; thus observational studies are sometimes needed
to assess the applicability of randomized study ﬁndings to
the general population.9,10
The reduction of LVM reported in randomized clinical trials
is variable in relation to selected populations, type of
medication, duration of trial, and type of design, but can be
estimated to be 8% to 14% over 2 to 48 months of
treatment.11 Whether such an effective reduction of LVM
can be achieved in usual clinical contexts or in unselected
free-living populations is often assumed, but remains to be
proven. Accordingly, this analysis has been designed to
compare changes in LVM over a 4-year follow-up in the
unselected cohort of treated hypertensive participants in the
Strong Heart Study (SHS), and to identify predictors of
modiﬁcations in LVM.
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Methods
Population
The SHS is a longitudinal population-based survey of cardio-
vascular risk factors and disease in American Indians from 13
communities in Arizona, Oklahoma, and South and North
Dakota.12 The fourth SHS examination, conducted between
2001 and 2003, enrolled 3658 individuals who were members
of large 3-generation families (the Strong Heart Family Study),
of which 520 were members of the original SHS cohort.13,14
Among them, 1133 hypertensive participants without valve
regurgitation greater than mild and without valve stenosis of
any degree were identiﬁed, 862 (76%) of whom underwent a
repeated echocardiogram after 4 years at the time of the ﬁfth
SHS exam. For the purpose of this analysis, participants with
triglycerides >750 mg/dL were excluded (n=11), consistent
with our previous reports.15 Thus, the analyzed population
sample included 851 participants, of whom 488 (57%) were
women.
Procedures
Clinical examinations, including a personal interview, physical
exam, and morning blood sample collection after a 12-hour
fast were performed at local community settings and Indian
Health Service clinics by the study staff. Detailed descriptions
of the study design and methods of the SHS have been
previously reported.12–14
Brachial systolic and diastolic BP (SBP and DBP) were
measured 3 consecutive times on seated participants using
appropriately sized cuffs. The mean of the last 2 of these
measurements was used to record BP levels. Diabetes
mellitus (DM) was deﬁned by fasting glucose ≥126 mg/dL
or use of insulin or oral hypoglycemic therapy.
Echocardiographic Measures
Echocardiograms were performed by expert sonographers,
according to standardized methods, and reviewed ofﬂine by
2 independent readers,16 following American Society of
Echocardiography recommendations.17 The LVM was calcu-
lated by a necropsy-validated formula18 and was normalized
for height in meter to the power of 2.7, an allometric signal
that linearizes the curvilinear relation between LVM and
height across a wide age range.19 LVH was deﬁned using a
nonsex-speciﬁc population-speciﬁc partition values, which
maximizes the population risk attributable to LVH (47.24 g/
m2.7).20
Variations of at least 5% of the initial values of both SBP
or LVM index (LVMi, in g/m2.7) were categorized for
analysis.
Statistical Analysis
Data were analyzed using SPSS 20.0 (IBM). Indicator variables
were included in all multivariable analyses for the 3 ﬁeld
centers. Exploratory statistics were run to ﬁnd the potential
confounders to be used in multivariable analyses, using chi-
square distribution for categories (with Monte Carlo method
for computation of exact 2-tailed P value, when appropriate)
analysis of variance and least square linear regression. Full-
factorial 2-way analysis of variance for repeated measures
was used to verify the time course of variables potentially
inﬂuencing variations of LVM and to explore possible sex-
related differences. Baseline demographic and metabolic
characteristics were compared in male and female partici-
pants with or without reduction of LVM, using 2-way analysis
of covariance, adjusted for baseline LVMi and the percent
changes in SBP.
The impact of family relatedness was considered in multi-
variable analyses, as previously reported21 by using standard
kinship coefﬁcients (0.25 for parent/offspring, 0.25 for full
siblings, 0.125 for half siblings, 0 for no consanguinity). Binary,
multivariable logistic regression was used to identify initial
characteristics of participants who did not change or increased
LVMi over time, using a hierarchical model in 3 steps. In the ﬁrst
step, critical adjusting variables were entered (age, sex, family
relatedness, baseline blood pressure and change in blood
pressure). In a second step, a backward stepwise procedure
was run including all variables that, at baseline, differed
between participants with or without reduction of LVMi, to
identify a phenotype with high probability of preserving or
increasing LVM. In the third step, classes of antihypertensive
medications were forced into the model to verify whether
antihypertensive treatment could modify the phenotype asso-
ciated with lack of reduction of LVM. In multivariable logistic
analysis modeling, kinship coefﬁcient was ﬁrst entered
together with the other critical adjusting variables.
Results
The population sample (Table 1) was characterized by a slight
predominance of women, who were younger than men
(4515 versus 5414 years, P<0.0001), with a high pre-
valence of overweight and obesity, and a high prevalence of
diabetes. Eighty-one percent of the hypertensive participants
were on antihypertensive medications.
Characteristics of the Population Sample
Compared with the baseline (fourth) exam, SBP decreased in
343 (40%) participants, increased in 270 (32%) and remained
unchanged in 238 (28%). On average, SBP decreased
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signiﬁcantly only in men (Figure), whereas DBP decreased
signiﬁcantly in both men and women (all P<0.0001). Table 2
includes the initial distribution of antihypertensive medica-
tions in the 3 subgroups of participants. The subgroup
with increase in follow-up BP were more likely to take
ACE-inhibitors, b-blockers, and Ca2+-channel blockers than
the other subgroups, whereas no difference was found for
diuretics, angiotensin II-receptor blockers, a-blockers and
other medications.
Body mass index (BMI) was similar in women and men and
was unchanged after 4 years (Table 3), but in men there was a
tendency to increase. Waist/hip ratio increased especially in
women. Triglycerides decreased in both men and women.
Glomerular ﬁltration rates decreased similarly in men and
women and urinary albumin/creatinine ratio slightly
increased. While DBP was reduced in both genders, SBP
decreased signiﬁcantly more in men than in women. No other
signiﬁcant changes or interactions could be detected.
Change of LVMi Over Time
At the time of the baseline exam LVH was found in 262 (31%)
participants and in 309 (36%) at the follow-up exam. At
baseline, 23% of men and 36% of women exhibited LVH
(P<0.0001 between genders). At the time of the follow-up
exam only 3% of men and 10% of women had clear-cut LVH
regression (P<0.0001 between genders). In contrast, 14% of
men and 15% of women who did not have LVH at the baseline
developed LVH during the 4 years of follow-up.
Average LVMi increased from the fourth (43.89.9 g/m2.7)
to the ﬁfth exam (44.910.5 g/m2.7, P=0.0001). This
increase was due to greater changes in men than in women
(P<0.001 between genders). Baseline LVMi was signiﬁcantly
greater in participants decreasing than in those increasing or
maintaining their LVM during follow-up (44.39.8 and
41.48.4 g/m2.7 in men; 47.011.7 and 44.59.9 g/m2.7
in women, respectively, P<0.002). Percent change of LVMi
was weakly related to percent change of SBP (r=0.18) and
follow-up SBP (r=0.19) and DBP (r=0.14; all P<0.01).
We performed a sex-speciﬁc comparison between partic-
ipants decreasing or not decreasing (or increasing) their LVMi
during follow-up, adjusting for changes in SBP, for baseline
values of LVMi and for degree of family relatedness (Table 4).
Participants who did not decrease their LVM were slightly, but
not signiﬁcantly, older than those with reduction of LVM. In
Table 1. Demographic Characteristics of the SHS










Central fat distribution, % 76
Diabetes, % 43
Untreated hypertension, % 19
Current smokers, % 30
SHS indicates Strong Heart Study; BMI, body mass index.
Figure. Side-to-side box plots of left ventricular (LV) mass index at
baseline (white boxes) and after 4-year follow-up (dashed boxes) in
treated hypertensive women and men, participants of the Strong
Heart Study.
Table 2. Distribution of Antihypertensive Medications at the
Time of the 4th SHS Exam in Participants Exhibiting Reduced,













ACE-inhibitors 41% 38% 53% ≤0.001
ARB 3.8% 5.5% 5.2% ≤0.58
b-Blockers 8.7% 6.3% 15.2% ≤0.002
CCB 13.4% 13.4% 21.1% ≤0.02
Diuretics 19.5% 16.4% 21.9% ≤0.30
a-Blockers 3.2% 1.7% 1.5% ≤0.28
Others 3.2% 1.3% 3.3% ≤0.27
SHS indicates Strong Heart Study; BP, blood pressure; ACE, angiotensin-converting
enzyme; ARB, angiotensin receptor blockers; CCB, Ca2+ channel blockers.
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addition, they had similar SBP and DBP, substantially higher
BMI, waist/hip ratio, and heart rate (all P<0.004), and
signiﬁcantly higher urinary albumin/creatinine ratio
(P<0.001). No differences could be found in fasting glucose
and lipid proﬁle. The differences between average values of
BMI and waist/hip ratio in participants with or without
reduction of LVM were marginally greater in men than in
women, but no other gender-differences were observed.
Lack of decrease in LVMi was not related to any class of
medications used at the baseline (data not shown). In
multivariable, multistep logistic regression, adjusting for ﬁeld
center, age, sex, degree of relatedness, initial LVMi, follow-up
BP, and change of SBP as percent of baseline values (Table 5),
lack of decrease in LVMi was associated with initially higher
BMI and urinary albumin/creatinine excretion independently
of signiﬁcant effects of older age, male gender, and change in
Table 3. Initial and Follow-Up CV Proﬁle in Female and Male Participants in the Present Study
Men (n=363), 5414 Years Women (n=488), 4515 Years
Baseline 4-Year Follow-Up Baseline 4-Year Follow-Up
Heart rate, bpm 69.111.7 68.811.4 68.810.8 68.210.4
BMI, kg/m2 33.66.7 34.17.8 34.37.1 34.57.3
Waist/hip ratio*† 0.980.07 0.990.06 0.910.06 0.940.06
Systolic BP*†, mm Hg 13717 13218 13518 13421
Diastolic BP*, mm Hg 8712 8013 7913 7213
Fasting glucose, mmol/L 6.943.00 7.323.44 7.553.61 7.603.72
HDL-cholesterol, mmol/L 1.270.42 1.210.37 1.380.39 1.330.38
Triglycerides*, mmol/L 2.161.27 1.921.13 2.081.02 1.851.06
GFR*, mL/min per 1.73 m2 10028 9333 8829 7832
Urinary albumin/creatinine* 10.2 (5.5 to 35.5) 11.0 (5.2 to 61.9) 12.5 (6.8 to 41.8) 14.0 (6.8 to 36.3)
CV indicates cardiovascular; BMI, body mass index; BP, blood pressure; HDL, high-density lipoprotein; GFR, glomerular ﬁltration rate.
*0.02<P<0.0001, time effect.
†0.003<P<0.001 interaction between time and sex.
Table 4. Initial Characteristics in Male and Female SHS Participants With or Without Reduction of LVMi During Follow-Up
Men (n=363), 5414 Years Women (n=488), 4515 Years
P Value < for
Change in LVM













Age, y 4414 4515 5214 5414 0.22 0.60
Prevalence of diabetes, % 33 36 46 47 NS NS
Systolic BP, mm Hg 13919 13716 13619 13418 0.62 0.63
Diastolic BP, mm Hg 8913 8612 8012 7913 0.37 0.23
Heart rate, bpm 6611 7012 6710 6911 0.004 0.46
BMI, kg/m2 31.15.5 34.26.8 33.76.8 34.47.2 0.0001 0.04
Waist/hip ratio 0.960.06 0.990.07 0.900.06 0.910.06 0.001 0.05
Fasting glucose, mmol/L 6.552.22 7.053.16 7.273.44 7.603.61 0.15 0.50
HDL-cholesterol, mmol/L 1.320.46 1.260.41 1.400.36 1.380.40 0.30 0.40
Triglycerides, mmol/L 2.151.23 2.161.28 2.101.02 2.081.02 0.87 0.89
GFR, mL/min per 1.73 m2 10127 10028 9130 8728 0.33 0.83
Urinary albumin/creatinine 7.7 (5.2 to 21.5) 10.8 (5.6 to 39.1) 11.9 (6.6 to 30.3) 13.0 (7.0 to 49.4) 0.003 0.77
Except for age and prevalence of diabetes, comparisons are adjusted for changes in systolic BP, baseline values of LVMi and degree of family relatedness. SHS indicates Strong Heart
Study; LV indicates left ventricle; NS, not signiﬁcant; BP, blood pressure; LVMi, left ventricular mass index; HDL, high-density lipoprotein; GFR, glomerular ﬁltration rate.
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BP over time, and without additional contribution of initial
waist/hip ratio. Forcing all classes of antihypertensive
medications into the model did not substantially modify the
coefﬁcients displayed in Table 5 (data not shown).
As a conﬁrmation, we analyzed the subpopulation (n=526,
301 women) that exhibited target BP at the follow-up (ie, SBP
<140 and DBP <90: 12211/7111 mm Hg). Among the
151 participants who had baseline LVH (29%), 129 (85%)
remained with LVH at the follow-up, compared to the 22 (15%)
who exhibited regression of LVH (P<0.0001). The same
logistic model displayed in Table 5 was therefore performed
in this subpopulation, resulting in the same pattern of risk as
shown in Table 5, with high baseline BMI (OR=1.08/kg9m2;
95% CI=1.04 to 1.12, P<0.0001) and log10 urinary albumin/
creatinine (OR=1.78; 95% CI=1.23 to 2.56, P<0.002) as the
markers of risk of not reducing initial LVH despite good
control of BP (both P<0.0001), without additional effect of
change of SBP (P=0.247).
Discussion
The results of the present analysis, performed in a free-living
sample of treated hypertensive adults with high prevalence
of obesity and diabetes, suggest that antihypertensive
management may not effectively decrease LVM in usual
clinical care programs. The lack of effect is associated with
older age, initial central obesity, and kidney damage, but not
with the type of antihypertensive therapy. This analysis
strongly suggests that (1) in real-life context, persistent
obesity inhibits the attempt to reduce LVM; (2) the lack of
reduction of LVM in this setting is at least in part
independent of BP control and types of initial antihyperten-
sive medications, and is associated with renal damage; and
(3) results of clinical trials on regression of LVH cannot be
automatically applied to unselected free-living populations
receiving standard programs of primary cardiovascular
prevention.
The effect of obesity on BP control and reduction of LVM
has been increasingly examined. Obesity and its associated
metabolic abnormalities have been shown to substantially
reduce the chance of effective BP control, despite more
aggressive antihypertensive management.21,22 In the Camp-
aniaSalute Network, we have shown that the presence of
multiple metabolic risk factors (including obesity, lipid abnor-
malities and impaired fasting glucose), substantially reduces
the chance to achieve optimal BP control, despite more
aggressive management.23 Similar results were recently
reported by the French Nutrition and Health Survey,24 which
highlighted that the difﬁculty in the antihypertensive man-
agement could not be imputed to inadequate treatment. This
negative effect on BP is also translated into target organ
damage. In the Losartan Intervention for Endpoint Reduction
in Hypertension (LIFE) study, clusters of metabolic risk
factors, including obesity, were associated with less reduction
of electrocardiogram-LVH in both diabetic and nondiabetic
groups.25 Similar ﬁndings were produced in 875 patients
recruited in the LIFE echo substudy.25,26 One of the reasons in
the lack of reduction of LVM in obesity might be in the
myocardial composition of obese subjects. The nonmuscular
component of myocardium in obesity is likely to be large, as a
number of studies suggest,27 being formed of adipocytes and
preadipocytes in addition to possibly large population of
ﬁbroblasts, all cell components that do not respond (or
respond much less than cardiomyocytes) to modiﬁcation of
loading conditions.
The partial independence of modiﬁcation of LVM from
loading conditions is sustained by the evidence that the lack of
Table 5. Predictors of Lack of Reduction of LVMi in Treated
Hypertensive Subjects





Age, y 0.02 <0.007 1.02 1.01 to 1.04
Female
sex (n/y)
0.57 <0.003 0.56 0.38 to 0.83
Degree of family
relatedness*




0.06 <0.0001 0.94 0.92 to 0.96
Baseline BMI,
kg/m2
0.08 <0.0001 1.08 1.05 to 1.12
Baseline systolic
BP, mm Hg

















0.49 <0.08 0.61 0.36 to 1.06
Constant 2.29 <0.07 — —
LVMi indicates left ventricle mass index; LV, left ventricle; CI, conﬁdence interval; OR,
odds ratio; BMI, body mass index; BP, blood pressure.
*Kinship coefﬁcients: 0.25 for parent/offspring, 0.25 for full siblings, 0.125 for half
siblings, and 0 for no consanguinity.
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reduction of LVMi in the SHS is substantially independent of
BP control. This independence was already evident in the
multivariable logistic analysis, but was eventually demon-
strated by analyzing all participants with effective BP control at
the end of follow-up, which conﬁrmed the results found in the
entire population sample. Thus the association with obesity
cannot be attributable to lack of BP control or adherence to
medications. In contrast, lack of reduction of LVM is clearly
associated with renal damage. These ﬁndings are made even
more relevant because the rate of BP control at the time of
follow-up was excellent (62%), as compared to baseline (n=360
or 42%, P<0.0001), and greater than generally reported in the
literature.28 The discrepancy between BP control and persis-
tence of initial values of LVMi is consistent with a number of
previous ﬁndings, suggesting that the paradigm of BP-LVH as
cause effect relation should be revised to recognize the role of
potentially interfering parameters.29 Increased LVM has been
shown to precede development of arterial hypertension in a
number of clinical and epidemiological studies,30–33 a ﬁnding
that supports a reverse-causation speculation29,34 and helps
explain why therapeutic intervention may control BP (the
effect), and much less LVM (one of the potential determinants
under this scenario).
Unfortunately a more extensive analysis of the potential
effect of therapy could not be done because only the
association with the initial treatment could be analyzed
leaving a lack of information on variation of treatment during
the follow-up. It is interesting that all major classes of
medications tended to be used more in those participants
who did not exhibit reduction of LVM, suggesting that already
at the beginning of the study more aggressive therapy was
indicated. Also, day-to-day or even week-to-week variability of
BP and LVM could be important, but would unlikely be known
in a real-world context.
Our results are obtained in normal community-based
settings, without the typical randomized controlled trial
(RCT) restraints. This is the greatest difference from the
RCT environment, which is usually conﬁned to patients with
some speciﬁc characteristics.
Finally, the generalizability of ﬁndings from RCTs has been
questioned by many researchers, and the need for transla-
tional research and postmarketing studies has been increas-
ingly emphasized.9,10,35,36 Our ﬁndings raise speculation
about the applicability of results of clinical trials to clinical
practice. Cuspidi et al8 highlighted that the results of trials on
regression of LVH are not necessarily automatically applica-
ble in clinical practice, due to a number of factors, including
the variability of the deﬁnition of hypertensive LVH and the
lack of information on rates of regression of LVH or reduction
of LVM, 2 terms that are not necessarily equivalent.37 In
addition, by design, clinical trials of regression of hyperten-
sive LVH have enrolled patients with BP levels that could be
substantially reduced (eg, by 22/13 mm Hg in Prospective
Randomized Enalapril Study Evaluating Regression of Ven-
tricular Enlargement (PRESEVE)38 and by 25/15 mm Hg in
the LIFE echo substudy,1 both of which showed substantial
LVH regression).
The selection made by many clinical trials, designed to
assess efﬁcacy of therapy on reduction of LVM or regression
of LVH, is rigorous and often the study-cohorts do not reﬂect
the variety of circumstances and conditions presenting with
hypertensive patients in clinical practice. This is particularly
evident for obesity, because, in a number of echocardio-
graphic studies, there was a lower prevalence of obesity in
the study cohort than in free-living hypertensives, due to
well-known technical problems in performing high-quality
echocardiograms that yield accurate, reproducible measure-
ments.39 The ability to obtain readable echocardiograms in
obese patients is increasing over time,40 but is still below that
of nonobese members of the general population,41 and may
be lower in unselected clinical outpatient hypertensive
populations than in participants in trials of LVH regression.
The SHS cohort provides a unique opportunity because of the
very high rate of readable echocardiograms, despite the very
high prevalence of obesity.42
Our ﬁndings need to be considered with caution, because
the speciﬁc characteristics of the SHS population (ethnicity,
prevalence of obesity and diabetes) preclude generalization.
However, preliminary ﬁndings from the CampaniaSalute
network, a large registry of whites from southern Italy,43
suggest that the relations between hypertensive LVM and BMI
might be very similar to what has been reported in the
participants of the SHS.44
Conclusions
This analysis demonstrates that, in a free-living sample of
hypertensive participants from a population-based study with
high prevalence of obesity, hypertensive LVH is commonly
sustained or may develop despite effective antihypertensive
therapy, contrary to expectations from results of randomized
controlled trials. Persistence or development of LVH in treated
hypertensive adults appears to be independent of blood
pressure control and is associated with persistent obesity and
renal damage.
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